Brief: Neurosense Receives U.S. FDA Confirmation Of CMC Strategy For Primec

Neurosense Therapeutics

13/11/2023 15:09

Nov 13 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE RECEIVES U.S. FDA CONFIRMATION OF CMC STRATEGY
FOR
PRIMEC IN PREPARATION FOR PIVOTAL PHASE 3 IN ALS AND COMMERCIAL
READINESS

Source text for Eikon:  ID:nPnbpK8Kma 
Further company coverage:  NRSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))